RT Journal Article
T1 International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study.
A1 de Aguirre-Neto, Joaquim Caetano
A1 de Camargo, Beatriz
A1 van Tinteren, Harm
A1 Bergeron, Christophe
A1 Brok, Jesper
A1 Ramírez-Villar, Gema
A1 Verschuur, Arnauld
A1 Furtwängler, Rhoikos
A1 Howell, Lisa
A1 Saunders, Daniel
A1 Olsen, Oystein
A1 Coulomb, Aurore
A1 Vokuhl, Christian
A1 Godzinski, Jan
A1 Smets, Anne M
A1 Vujanic, Gordan M
A1 van den Heuvel-Eibrink, Marry M
A1 Graf, Norbert
A1 Pritchard-Jones, Kathy
AB International comparisons of patient demographics, tumor characteristics, and survival can shed light on areas for health care system improvement. The International Society of Pediatric Oncology Wilms Tumor 2001 trial/study registered patients through national clinical study groups in Western Europe and Brazil. This retrospective post hoc analysis of the International Society of Pediatric Oncology Wilms Tumor 2001 database aims to make visible and suggest reasons for any variations in outcomes. All patients with unilateral Wilms tumor (WT), age > 6 months, treated with preoperative chemotherapy as per protocol, and registered between 2001 and 2011 were eligible. Countries were grouped to give comparable case numbers and geographical representation. Cox univariable and multivariable (MVA) statistics were applied, with the German collaborative group (Gesellschaft für Pädiatrische Onkologie und Hämatologie-Austria, Germany, and Switzerland) as reference for hazard ratios for event-free survival (EFS) and overall survival (OS). A total of 3,176 eligible patients were registered from 24 countries assigned into six groups. Age and histologic risk group distribution were similar across all groupings. The distribution of WT stage varied by country grouping, with 14.9% (range, 11.1%-18.2%) metastatic at diagnosis. Median follow-up was 78.9 months. For localized WT, 5-year EFS varied from 80% (Brazilian group) to 91% (French group; P  International benchmarking of survival rates from WT within a large trial/study database has demonstrated statistically significant differences. Clinical interpretation should take account of variation in tumor stage but also treatment factors.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/20384
UL http://hdl.handle.net/10668/20384
LA en
DS RISalud
RD Apr 9, 2025